[to the editor:]{.smallcaps} Coronavirus disease (COVID-19) is an emerging pandemic. Clinical manifestations of COVID-19 range from asymptomatic to acute respiratory distress syndrome (ARDS) ([@B6], [@B11], [@B12], [@B20], [@B23]).

Preliminary data on COVID-19 suggest hypertension to be correlated with worse outcomes (23.2%) compared with that of other metabolic disorders. This observation has been postulated to be correlated with use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) rather than hypertension. This alleged correlation has been disseminated among medical communities and media and has encouraged physicians to withdraw use of these drugs from COVID-19 patients.

The potential harm from inappropriate discontinuation of ACEIs/ARBs has led to communication ([@B1], [@B5]) recommending against withdrawal. Two recent reports ([@B17], [@B18]) have stated there are insufficient data to support speculations on the consequences of ACEIs/ARBs use in COVID-19.

The hypothesized rationale for the possible (but controversial) correlation between ACEIs and ARBs and progression to ARDS in COVID-19 is based on reports that the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a strong interaction with the angiotensin-converting enzyme-2 receptor (ACE-2R) ([@B7], [@B10], [@B13], [@B22]). Hence, an increase in expression of ACE-2Rs attached to cell surfaces in lung endothelia could amplify the capacity of SARS-CoV-2 to enter pulmonary cells. The only study to evaluate ACEI use for long periods demonstrated an increase in levels of angiotensin 1--7 (an indirect marker of ACE-2 action in the lung), which better reflects typical chronic use of ACEIs/ARBs ([@B14]).

Although attached ACE-2 may allow SARS-CoV-2 to enter cells, its free circulating forms may inactivate SARS-CoV-2 by stopping coupling to membrane ACE-2Rs and consequent entry into pulmonary endothelial cells ([@B1], [@B10], [@B21]). Recombinant human soluble ACE-2 has been proposed to protect against ARDS and death in COVID-19 ([@B2], [@B21]). Soluble ACE-2 is commercially unavailable, unaffordable, produced at insufficient scales, and lacks definitive data ([@B4]).

The circulating plasma level of ACE-2 may be insufficient to protect membrane-attached ACE-2Rs from coupling with SARS-CoV-2 ([@B2]), but, under particular conditions (e.g., soluble ACE-2), the protective actions of ACE-2 may become relevant. In addition to soluble ACE-2, potassium-sparing diuretics \[another class of antihypertensive drug that also acts in the renin--angiotensin--aldosterone system (RAAS)\] and its main representative, spironolactone, have been reported to increase ACE-2 expression in plasma by 3- to-5-fold ([@B2], [@B9], [@B19]), in contrast with the possibly unaffected plasma ACE-2 activity when using ACEIs/ARBs ([@B2], [@B4], [@B8], [@B21])

Spironolactone could, theoretically, reduce ACE-2 expression on lung-cell surfaces, because, unlike ACEIs/ARBs, it does not act in the pulmonary RAAS. Although renin levels are enhanced when using ACEIs, ARBs, or potassium-sparing diuretics, the difference between the sites of blockade of renin effects may lead to a contrary metabolic microenvironment in the RAAS in the lungs ([@B3], [@B15], [@B16]).

Hence, switching ACEIs/ARBs for spironolactone could address the above-mentioned concerns, because spironolactone can prevent the effects of ACEI/ARB withdrawal ([@B2]), which has not been considered previously ([@B6]--[@B9]). Furthermore, despite the outstanding quality of studies by Vaduganathan and colleagues ([@B18]) and South and coworkers ([@B17]), the differentiation between circulating and cell-surface levels of ACE-2 in those reports was blurred, which hampers accurate mechanistic analysis.

The benefits of spironolactone, its extensively validated safety/risk profile, and its ability to substitute for ACEIs/ARBs appropriately would allow this switch without major ethical concerns in selected patients.

With regard to the difference in ACE-2 activity in plasma and cell surfaces, use of ACEIs/ARBs could be a risk factor, but this is speculative and dependent on more robust data. Use of spironolactone may address issues of withdrawal of ACEIs/ARBs and simultaneously rebalance plasma and cell-membrane levels of ACE-2.
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